Literature DB >> 23887359

Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.

Ismail Kocyigit1, Mahmut Ilker Yilmaz, Ozcan Orscelik, Murat Hayri Sipahioglu, Aydin Unal, Eray Eroglu, Nihat Kalay, Bulent Tokgoz, Jonas Axelsson, Oktay Oymak.   

Abstract

BACKGROUND/AIMS: Patients with autosomal dominant polycystic kidney disease (ADPKD) exhibit endothelial dysfunction (ED) despite normal levels of renal function. Hyperuricemia occurs in these patients and has been postulated to affect ED through the generation of oxidative stress. We therefore investigated the prevalence of ED and its association with serum uric acid levels in early-stage ADPKD.
METHODS: A cross-sectional design was used for the assessment of prevalent patients with early-stage (normal renal function) ADPKD (n = 91) from two academic medical centers. ED was assessed using ischemia-induced forearm flow-mediated vasodilation (FMD). Serum uric acid levels were evaluated using an Olympus AU2700 autoanalyzer.
RESULTS: ADPKD patients with higher serum uric acid levels had a higher asymmetric dimethylarginine (ADMA) level (1.19 ± 0.2 vs. 1.47 ± 0.3, p < 0.001) and lower FMD rates (8.1 ± 1.3 vs. 6.8 ± 0.7, p < 0.001). In multiple regression analysis for predictors of cohort FMD, uric acid (β = -0.32, p < 0.001), ADMA (β = -0.36, p < 0.001), high-sensitivity C reactive protein (CRP; β = -0.32, p < 0.001) and estimated glomerular filtration rate (eGFR; β = 0.33, p < 0.001) all predicted FMD.
CONCLUSIONS: In early-stage ADPKD patients, uric acid levels, serum ADMA and eGFR all independently predict ED in a similar manner. Future studies are needed to investigate the causes of elevated serum uric acid, ADMA and CRP in these patients.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23887359     DOI: 10.1159/000353730

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  12 in total

Review 1.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

2.  Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease.

Authors:  Ismail Kocyigit; Serpil Taheri; Elif Funda Sener; Aydin Unal; Eray Eroglu; Fahir Öztürk; Kezban Korkmaz; Gokmen Zararsiz; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak
Journal:  Cardiorenal Med       Date:  2014-12-10       Impact factor: 2.041

3.  Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease.

Authors:  Ismail Kocyigit; Eray Eroglu; Ozcan Orscelik; Aydin Unal; Ozkan Gungor; Fahir Ozturk; Cigdem Karakukcu; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak
Journal:  J Nephrol       Date:  2014-02-11       Impact factor: 3.902

Review 4.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

5.  Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors:  Asmin Andries; Kristien Daenen; François Jouret; Bert Bammens; Djalila Mekahli; Ann Van Schepdael
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

6.  Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease.

Authors:  Ismail Kocyigit; Mahmut Ilker Yilmaz; Ozkan Gungor; Eray Eroglu; Aydin Unal; Ozcan Orscelik; Bulent Tokgoz; Murat Sipahioglu; Ahmet Sen; Juan Jesús Carrero; Oktay Oymak; Jonas Axelsson
Journal:  BMC Nephrol       Date:  2016-11-30       Impact factor: 2.388

7.  Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.

Authors:  Godela M Brosnahan; Zhiying You; Wei Wang; Berenice Y Gitomer; Michel Chonchol
Journal:  Curr Hypertens Rev       Date:  2021

8.  Relationships of Hyperhomocysteinemia and Hyperuricemia With Metabolic Syndrome and Renal Function in Chinese Centenarians.

Authors:  Shihui Fu; Yao Yao; Yali Zhao; Fuxin Luan
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-11       Impact factor: 5.555

9.  Clinical burden of autosomal dominant polycystic kidney disease.

Authors:  Peir-Haur Hung; Chien-Hung Lin; Kuan-Yu Hung; Chih-Hsin Muo; Mu-Chi Chung; Chao-Hsiang Chang; Chi-Jung Chung
Journal:  Aging (Albany NY)       Date:  2020-02-24       Impact factor: 5.682

10.  Association between serum uric acid level and endothelial dysfunction in elderly individuals with untreated mild hypertension.

Authors:  Guo-Hua Zhu; Xi-Peng Sun; Jing Li; Rong-Kun Liu; Zheng Yang; Qi Hua
Journal:  J Geriatr Cardiol       Date:  2020-05       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.